Tech Company Financing Transactions
Portola Pharmaceuticals Funding Round
Portola Pharmaceuticals, based in South San Francisco, secured $46 million from Advanced Technology Ventures, Abingworth and Alta Partners.
Transaction Overview
Company Name
Announced On
11/8/2005
Transaction Type
Venture Equity
Amount
$46,000,000
Round
Series B
Investors
Advanced Technology Ventures (Lead Investor) (Jean George)
Alta Partners (Farah Champsi)
Proceeds Purpose
The Series B funds will advance our lead program, an oral Factor Xa inhibitor, into phase II clinical trials in 2006, and bring our ADP receptor antagonist program, aimed at the $7 billion anti-platelet market, into the clinic.
Company Information
Company Status
Acquired or Merged
Industry
Biopharmaceutical
Mailing Address
270 E. Grand Ave.
South San Francisco, CA 94080
USA
South San Francisco, CA 94080
USA
Phone
Website
Email Address
Overview
Portola Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapeutics for acute and chronic cardiovascular and vascular disease. Portola has two drug candidates in clinical development.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Financial Officer
Mard Dier
Chief Medical Officer
John Lawrence?
VP - Bus. Development
Tao Fu
VP - Engineering
Glenn Brame
VP - General Counsel
John Moriarty
VP - R & D
John Curnutte
Browse more venture capital transactions:
Prev: 11/7/2005: NexTone Communications venture capital transaction
Next: 11/8/2005: NuPathe venture capital transaction
Share this article
About Database of VC Transactions
We report on every notable VC transaction. VC investment data records on this site are sourced from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs